Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
about
A phase I and pharmacokinetic study of intraperitoneal topotecanThree inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replicationTopotecan inhibits human immunodeficiency virus type 1 infection through a topoisomerase-independent mechanism in a cell line with altered topoisomerase IEvaluation of topotecan and etoposide for non-Hodgkin lymphoma: correlation of topoisomerase-DNA complex formation with clinical response.Phase II study to topotecan and cisplatin in advanced hepatocellular carcinoma.Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeksA phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer.A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors.Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors.Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administrationThe bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma.Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacyTreatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803).MicroRNA 506 regulates expression of PPAR alpha in hydroxycamptothecin-resistant human colon cancer cells.Topotecan in the treatment of relapsed small cell lung cancer.Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissuesAntagonism of cytotoxic chemotherapy in neuroblastoma cell lines by 13-cis-retinoic acid is mediated by the antiapoptotic Bcl-2 family proteinsTopotecan-based combination chemotherapy in patients with transformed chronic myelogenous leukemia and advanced myelodysplastic syndromeSuccessful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenograftsBioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumoursCancer therapies utilizing the camptothecins: a review of the in vivo literatureDose escalation methods in phase I cancer clinical trials.Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues.Topoisomerase I inhibitors and drug resistanceSmac mimetic LCL161 supports neuroblastoma chemotherapy in a drug class-dependent manner and synergistically interacts with ALK inhibitor TAE684 in cells with ALK mutation F1174L.Topotecan: a new topoisomerase I inhibiting antineoplastic agent.Current perspectives on camptothecins in cancer treatmentA phase II study of topotecan in non-Hodgkin's lymphoma: an Ohio State University phase II research consortium study.SWOG-9510: evaluation of topotecan in hormone refractory prostate cancer: a Southwest Oncology Group study.Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.Population pharmacokinetics/pharmacodynamics relationships of an anticancer drug.Safety, tolerability, pharmacokinetics, and pharmacodynamics of an orally active novel camptothecin analog, DRF-1042, in refractory cancer patients in a phase I dose escalation study.Efficacy of topotecan treatment on antioxidant enzymes and TBA-RS levels in submandibular glands of rabbits: an experimental study.Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol.
P2860
Q28366214-E8DC5650-4F9D-4EC9-AAAC-2C4474ED0262Q28378673-5823728C-8513-4AF5-ABCA-BFC64D08E245Q28378884-E57C85E9-408D-4EBF-A673-04629CBCE6E7Q31911584-F7B51BF5-DFE9-499D-A741-0E0A92802682Q33349102-C7C1F70A-EBED-4EF4-B77E-56F25064799AQ33360843-91975450-A57F-4B5D-8B2E-A7807048EA32Q33368776-2B5920F3-4054-42C0-B8C6-D7C6B1EE0460Q33386523-F740E128-9EE6-4A62-AD72-9E7812C92663Q33411718-40DFDF05-ED3E-4240-A10E-32DEFDD03DD3Q33412801-5DE9596D-FE57-4BF4-B0A6-7A59978C4B78Q33495553-728FE585-D941-4A3D-AD3E-727B5096862EQ33500497-F010DA93-E709-4392-B768-A932683023A0Q33500679-85FF8DD3-99E0-41E7-848A-05AB6629D2B9Q33501194-CB611C93-40F1-4335-9ADC-A800FE16B9B4Q33920750-37EA1E63-1659-4F1C-B263-2D003DC41BBBQ34228500-E7F25460-1F71-474C-A812-E11C82356CD2Q34363428-68090BA1-091A-4753-8431-1F58FFF85733Q34531543-522E634F-AA63-4C39-9A9D-4043579156CFQ35238042-65E6A287-98DD-4724-B7D0-622B2171151CQ35937752-0C9BDEB2-93A0-4C4D-B858-43BCBFB906B8Q36080470-90517716-ACD1-49AD-92B4-E1CB816E1A18Q36135270-3F0B3A43-F213-4B25-A31A-2EA26D1F43E3Q36292082-ECF4282C-2180-41D3-9AF5-6F14994E9EDCQ36431537-4D0A08F7-0B6F-42B3-8F1B-F44BDEFB0AADQ36431807-36DD9264-A59A-4125-A929-FA306661CB99Q36614847-DF8E5349-DB0C-412C-95C9-6547F42FC770Q37069556-82BB6272-B7B0-4849-AF45-41341B4DE64AQ37198192-36F3309C-4880-4530-B594-401164C3CF7AQ39150971-8F6D3709-E531-41E4-A610-52F4F694A6E3Q40028536-753B9247-CF19-4424-AA00-1CECE7611D6AQ41840140-013B697A-B77B-476C-A75F-4E95E2982FFEQ42689189-353BC5E4-B65E-4227-B317-9745FFD9113BQ42715927-3F0F8513-302A-45B3-9E65-9B3CC0A0FDECQ43922182-5D60A303-6A53-48A5-8F34-AF77875E1B9EQ44124770-1291B4DF-38FD-4488-B8B7-1E85D50FEA3AQ44168595-A40049A1-0E3A-4C77-8709-ED4B34399689Q44355934-2E6F1B5D-33A8-4658-8DEF-A682C44B0F33Q44938157-5702B2C4-EC88-4A74-9B36-3C955897BCAAQ45212110-F18978C4-77A7-4102-BBB5-A6AC9108D858Q46963348-07A7C693-7224-4B7E-83D8-7054F0BBA54B
P2860
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
description
1992 nî lūn-bûn
@nan
1992 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
@ast
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
@en
type
label
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
@ast
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
@en
prefLabel
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
@ast
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
@en
P2093
P1476
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
@en
P2093
A A Forastiere
B G Lubejko
C B Hendricks
D S Ettinger
E K Rowinsky
L A Hurowitz
L B Grochow
S E Sartorius
S H Kaufmann
W P McGuire
P304
P356
10.1200/JCO.1992.10.4.647
P407
P577
1992-04-01T00:00:00Z